Sudbrock F - Search Results

1

Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?

Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H. Kobe C, et al. Among authors: sudbrock f. Nuklearmedizin. 2008;47(1):13-7. Nuklearmedizin. 2008. PMID: 18278207

2

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H. Schmidt M, et al. Among authors: sudbrock f. Nuklearmedizin. 2006;45(4):145-51; quiz N39-40. Nuklearmedizin. 2006. PMID: 16964339

3

[Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].

Sudbrock F, Eschner W, Schmidt M, Simon T, Hero B, Schicha H. Sudbrock F, et al. Nuklearmedizin. 2006;45(6):254-61. Nuklearmedizin. 2006. PMID: 17149494 German.

4

Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?

Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, Schicha H. Kobe C, et al. Among authors: sudbrock f. Nuklearmedizin. 2008;47(4):153-6. Nuklearmedizin. 2008. PMID: 18690374

5

[Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 1: Diagnostic procedures].

Sudbrock F, Boldt F, Kobe C, Eschner W, Schicha H. Sudbrock F, et al. Nuklearmedizin. 2008;47(6):267-74. Nuklearmedizin. 2008. PMID: 19057801 German.

6

[Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].

Sudbrock F, Boldt F, Kobe C, Hammes J, Eschner W, Schicha H. Sudbrock F, et al. Nuklearmedizin. 2009;48(1):17-25. Nuklearmedizin. 2009. PMID: 19212607 German.

7

Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?

Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H. Kobe C, et al. Among authors: sudbrock f. Nucl Med Commun. 2010 Mar;31(3):201-5. doi: 10.1097/MNM.0b013e328333d303. Nucl Med Commun. 2010. PMID: 19907353

8

Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma.

Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Sudbrock F, et al. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1279-90. doi: 10.1007/s00259-010-1391-7. Epub 2010 Feb 24. Eur J Nucl Med Mol Imaging. 2010. PMID: 20179922

9

[Procedure guideline for sentinel lymph node diagnosis].

Vogt H, Schmidt M, Bares R, Brenner W, Grünwald F, Kopp J, Reiners C, Schober O, Schümichen C, Schicha H, Sciuk J, Sudbrock F, Wengenmair H. Vogt H, et al. Among authors: sudbrock f. Nuklearmedizin. 2010;49(4):167-72; quiz N19. doi: 10.3413/nukmed-321. Epub 2010 May 19. Nuklearmedizin. 2010. PMID: 20485862 German.

10

Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.

Schomäcker K, Sudbrock F, Fischer T, Dietlein M, Kobe C, Gaidouk M, Schicha H. Schomäcker K, et al. Among authors: sudbrock f. Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2165-72. doi: 10.1007/s00259-011-1888-8. Epub 2011 Aug 17. Eur J Nucl Med Mol Imaging. 2011. PMID: 21847636

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters